Held by 3 specialist biotech funds
High Convergence# Signal Note: RA Capital initiates $82.6M position in Arcellx (ACLX) RA Capital's substantial entry into ACLX signals conviction in the company's engineered cell therapy platform, likely driven by near-term catalysts around its lead candidate seribantumab (or pipeline progression data).
AI analyst context — unlock full analysis
# Signal Note: Perceptive Advisors Initiates $95.6M Position in Arcellx Perceptive's significant entry into ACLX likely reflects confidence in the company's lead candidate, semoloclax (CART-ddBCL2), a next-generation CAR-T targeting relapsed/refractory acute myeloid leukemia (AML)—a segment with limited treatment options and commercial runway. The timing aligns with anticipated clinical readouts expected in 2024-2025, with potential near-term catalysts in earlier-stage indications like B-cell lymphomas. Given Edelman's track record backing clinical-stage immunotherapies with differentiated mechanisms, this signals conviction in the program's risk-reward relative to competing CART approaches.
+ 1 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial